Moderna, Inc. (MRNA)
After hours:
| Previous close | 107.89 |
| Open | 111.00 |
| Bid | 108.82 x 100 |
| Ask | 108.94 x 100 |
| Day's range | 106.64 - 111.23 |
| 52-week range | 62.55 - 142.79 |
| Volume | |
| Avg. volume | 3,764,741 |
| Market cap | 41.676B |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.33 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 132.36 |
Investor's Business DailyAnalysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Moderna stock is under pressure and estimates have come down for its first quarter. Is MRNA stock now a sell?
ReutersPfizer vs Moderna battle over COVID vaccine patents begins in UK
Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed. Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.
Simply Wall St.Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness
In the last year, many Moderna, Inc. ( NASDAQ:MRNA ) insiders sold a substantial stake in the company which may have...
